Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ODTJN
ADC Name
WO2018098269A2 conjugate 57
Synonyms
WO2018098269A2_conjugate-57
   Click to Show/Hide
Organization
Mersana Therapeutics, Inc.
Drug Status
Investigative
Indication
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Gastric cancer [ICD11:2B72]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
Drug-to-Antibody Ratio
16.5
Antibody Name
XMT-1535
  Antibody Info 
Antigen Name
Sodium-dependent phosphate transport protein 2B (SLC34A2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
WO2018098269A2_conjugate 57 linker
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 54.09
%
CVCL_0465
Ovarian serous adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 98.71
%
CVCL_0465
Ovarian serous adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 99.72
%
CVCL_0465
Ovarian serous adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 54.09% (Day 30) Positive HER2 expression (HER2+++/++)
Method Description
Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (1.5 mg/kg) on day 1.
In Vivo Model OVCAR-3 CDX model
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 98.71% (Day 32) Positive HER2 expression (HER2+++/++)
Method Description
Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3 mg/kg) on day 1.
In Vivo Model OVCAR-3 CDX model
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.72% (Day 43) Positive HER2 expression (HER2+++/++)
Method Description
Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3 mg/kg) on day 1.
In Vivo Model OVCAR-3 CDX model
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
References
Ref 1 Peptide-containing linkers for antibody-drug conjugates.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.